How severe is CVE-2025-61940?

CVE-2025-61940 has a CVSS 3.x base score of 8.3, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability low.

Is CVE-2025-61940 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (21st percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2025-61940?

CVE-2025-61940 affects Mirion Biodose/nmis. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2025-61940?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

Does CVE-2025-61940 have an EU (EUVD) identifier?

Yes. CVE-2025-61940 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2025-200322.

When was CVE-2025-61940 published?

CVE-2025-61940 was published on 2025-12-02 and last updated on 2026-06-17.

CVE-2025-61940

CVE-2025-61940 is a high-severity vulnerability in Mirion Biodose/nmis with a CVSS 3.x base score of 8.3. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-603.

Key facts

Severity: High (CVSS 3.x base score 8.3)
CVSS v4: 8.7
EPSS exploit prediction: 0% (21st percentile)
Actively exploited: Not listed in CISA KEV
EU (EUVD) id: EUVD-2025-200322
Weakness: CWE-603
Affected product: Mirion Biodose/nmis
Published: 2025-12-02
Last modified: 2026-06-17

Description

NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.

Frequently asked questions

What is CVE-2025-61940?: NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.
How severe is CVE-2025-61940?: CVE-2025-61940 has a CVSS 3.x base score of 8.3, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability low.
Is CVE-2025-61940 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (21st percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2025-61940?: CVE-2025-61940 affects Mirion Biodose/nmis. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2025-61940?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
Does CVE-2025-61940 have an EU (EUVD) identifier?: Yes. CVE-2025-61940 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2025-200322.
When was CVE-2025-61940 published?: CVE-2025-61940 was published on 2025-12-02 and last updated on 2026-06-17.

References

https://www.cisa.gov/news-events/ics-medical-advisories/icsma-25-336-01

Affected products (1)

cpe:2.3:a:mirion:biodose\/nmis:*:*:*:*:*:*:*:*

More vulnerabilities in Mirion Biodose/nmis

CVE-2025-64298 — High (CVSS 8.4): NMIS/BioDose V22.02 and previous version installations where the embedded Microsoft SQLServer Express is used are…
CVE-2025-62575 — High (CVSS 8.3): NMIS/BioDose V22.02 and previous versions rely on a Microsoft SQL Server database. The SQL user account 'nmdbuser' and…
CVE-2025-64642 — High (CVSS 8.0): NMIS/BioDose V22.02 and previous versions' installation directory paths by default have insecure file permissions,…
CVE-2025-64778 — High (CVSS 7.3): NMIS/BioDose software V22.02 and previous versions contain executable binaries with plain text hard-coded passwords.…

All CVEs affecting Mirion Biodose/nmis →

Other CWE-603 vulnerabilities

CVE-2026-1363 — Critical (CVSS 9.8): IAQS and I6 developed by JNC has a Client-Side Enforcement of Server-Side Security vulnerability, allowing…
CVE-2025-12868 — Critical (CVSS 9.8): New Site Server developed by CyberTutor has a Use of Client-Side Authentication vulnerability, allowing unauthenticated…
CVE-2024-39375 — Critical (CVSS 9.8): TELSAT marKoni FM Transmitters are vulnerable to an attacker bypassing authentication and gaining administrator…
CVE-2022-33139 — Critical (CVSS 9.8): A vulnerability has been identified in Cerberus DMS (All versions), Desigo CC (All versions), Desigo CC Compact (All…
CVE-2025-64119 — Critical (CVSS 9.3): A vulnerability in Nuvation Battery Management System allows Authentication Bypass.This issue affects Battery…
CVE-2020-7591 — High (CVSS 8.8): A vulnerability has been identified in SIPORT MP (All versions < 3.2.1). Vulnerable versions of the device could allow…

Browse all CWE-603 vulnerabilities →